{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:10:07Z","timestamp":1790482207486,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004360","name":"Swedish University of Agricultural Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004360","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Mol and Cell Biol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Thymidine kinase 1 (TK1) plays a key role in the synthesis of deoxythymidine triphosphate (dTTP) and is thus important for DNA replication and cell proliferation. The expression of TK1 is highest during S-phase, and it is rapidly degraded after mitosis. In cancer cells, TK1 is upregulated, resulting in leakage of excess TK1 into the blood. Consequently, serum TK1 has been used as a diagnostic and prognostic cancer biomarker, mainly in human medicine. The aims of this work were to characterize equine TK1 and to evaluate its suitability as a serum biomarker for equine lymphoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Equine TK1 was cloned, expressed in <jats:italic>E. coli<\/jats:italic> and affinity purified. The purified recombinant horse TK1 showed broad substrate specificity, phosphorylating pyrimidine deoxyribo- and ribonucleosides and, to some extent, purine deoxynucleosides, including anticancer and antiviral nucleoside analogues. ATP was the preferred phosphate donor. Serum TK1 activity was measured in samples collected from horses with confirmed or suspected lymphoma and control horses with and without concurrent diseases. Serum TK1 activity levels were significantly higher in horses with lymphoma (<jats:italic>p<\/jats:italic>\u00a0&lt;\u2009\u00a00.0005) and suspected lymphoma (<jats:italic>p<\/jats:italic>\u00a0&lt;\u2009\u00a00.02) and in tumour-free groups with diverse diseases (<jats:italic>p<\/jats:italic>\u00a0&lt;\u2009\u00a00.03) than in controls without concurrent diseases. There was a significant difference between the lymphoma group and the tumour-free group with diverse diseases (<jats:italic>p<\/jats:italic>\u00a0&lt;\u2009\u00a00.0006). Furthermore, receiver operating characteristic analysis revealed a sensitivity of 0.86, a specificity of 0.95 and an AUC (area under the curve) of 0.92 compared to the controls without concurrent diseases, with a sensitivity of 0.97, a specificity of 0.71 and an AUC of 0.88 when compared with the tumour-free group with diverse diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Equine TK1 showed high specific activity and broader substrate specificity than human TK1. Anticancer and antiviral thymidine analogues were efficiently phosphorylated by horse TK1, suggesting that these analogues might be good candidates for chemotherapy in horses. Serum TK1 activity was significantly higher in horses with lymphoma than in controls. ROC analysis indicated that serum TK1 could serve as a promising cancer biomarker in horses.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12860-021-00399-x","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T09:06:11Z","timestamp":1639472771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecular characterization of equine thymidine kinase 1 and preliminary evaluation of its suitability as a serum biomarker for equine lymphoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Liya","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinzenz","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"R\u00f6nnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"issue":"3","key":"399_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/evj.12421","volume":"48","author":"E Knowles","year":"2016","unstructured":"Knowles E, Tremaine W, Pearson G, Mair T. A database survey of equine tumours in the United Kingdom. Equine Vet J. 2016;48(3):280\u20134. https:\/\/doi.org\/10.1111\/evj.12421.","journal-title":"Equine Vet J"},{"issue":"4","key":"399_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.2042-3292.2010.00200.x","volume":"23","author":"J Taintor","year":"2011","unstructured":"Taintor J, Schleis S. Equine lymphoma. Equine Vet Educ. 2011;23(4):205\u201313. https:\/\/doi.org\/10.1111\/j.2042-3292.2010.00200.x.","journal-title":"Equine Vet Educ"},{"issue":"6","key":"399_CR3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/j.1939-1676.2006.tb00762.x","volume":"20","author":"S Taylor","year":"2006","unstructured":"Taylor S, Pusterla N, Vaughan B, Whitcomb M, Wilson W. Intestinal neoplasia in horses. J Vet Intern Med. 2006;20(6):1429\u201336. https:\/\/doi.org\/10.1111\/j.1939-1676.2006.tb00762.x.","journal-title":"J Vet Intern Med"},{"key":"399_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/0300985812451603","volume":"50","author":"A Durham","year":"2012","unstructured":"Durham A, Pillitteri C, Myint M, Valli V. Two hundred three cases of equine lymphoma classified according to the world health organization (WHO) classification criteria. Vet Pathol. 2012;50:86\u201393.","journal-title":"Vet Pathol"},{"issue":"1","key":"399_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/1040638714561653","volume":"27","author":"C Miller","year":"2015","unstructured":"Miller C, Durham A, Schaeffer P, Ehrhart E, Powers B, Duncan C. Classification and clinical features in 88 cases of equine cutaneous lymphoma. J Vet Diagn Invest. 2015;27(1):86\u201391. https:\/\/doi.org\/10.1177\/1040638714561653.","journal-title":"J Vet Diagn Invest"},{"issue":"4","key":"399_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.2042-3292.2010.00036.x","volume":"22","author":"J Robertson","year":"2010","unstructured":"Robertson J. Dealing with neoplasia in elderly horses. Equine Vet Edu. 2010;22(4):163\u20134. https:\/\/doi.org\/10.1111\/j.2042-3292.2010.00036.x.","journal-title":"Equine Vet Edu"},{"issue":"12","key":"399_CR7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ejcb.2009.06.005","volume":"88","author":"F Gasparri","year":"2009","unstructured":"Gasparri F, Wang N, Skog S, Galvani A, Eriksson S. Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays. Eur J Cell Biol. 2009;88(12):779\u201385. https:\/\/doi.org\/10.1016\/j.ejcb.2009.06.005.","journal-title":"Eur J Cell Biol"},{"issue":"4-6","key":"399_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/15257770.2013.854383","volume":"33","author":"R Sun","year":"2014","unstructured":"Sun R, Eriksson S, Wang L. Mitochondrial thymidine kinase 2 but not deoxyguanosine kinase is up-regulated during stationary growth phase of the cultured cells. Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):282\u20136. https:\/\/doi.org\/10.1080\/15257770.2013.854383.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"2","key":"399_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1128\/MCB.24.2.514-526.2004","volume":"24","author":"PY Ke","year":"2004","unstructured":"Ke PY, Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex\/cyclosome-CDH1-mediated pathway. Mol Cell Biol. 2004;24(2):514\u201326. https:\/\/doi.org\/10.1128\/MCB.24.2.514-526.2004.","journal-title":"Mol Cell Biol"},{"issue":"12","key":"399_CR10","doi-asserted-by":"publisher","first-page":"11064","DOI":"10.3390\/s111211064","volume":"11","author":"Z Chen","year":"2011","unstructured":"Chen Z, Huang S, Wang Y, Yang A, Wen J, Xu X, et al. Serological thymidine kinase 1 is a biomarker for early detection of tumours - a health screening study on 35, 365 people using a sensitive chemiluminescent dot blot assay. Sensors (Basel). 2011;11(12):11064\u201380. https:\/\/doi.org\/10.3390\/s111211064.","journal-title":"Sensors (Basel)"},{"issue":"1","key":"399_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3892\/mco.2012.19","volume":"1","author":"J Zhou","year":"2013","unstructured":"Zhou J, He E, Skog S. The proliferation marker thymidine kinase 1 in clinical use. Mol Clin Oncol. 2013;1(1):18\u201328. https:\/\/doi.org\/10.3892\/mco.2012.19.","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"399_CR12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/j.1939-1676.2004.tb02608.x","volume":"18","author":"H von Euler","year":"2004","unstructured":"von Euler H, Einarsson R, Olsson U, Lagerstedt A-S, Eriksson S. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. J Vet Intern Med. 2004;18(5):696\u2013702. https:\/\/doi.org\/10.1111\/j.1939-1676.2004.tb02608.x.","journal-title":"J Vet Intern Med"},{"issue":"1","key":"399_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1476-5829.2010.00238.x","volume":"9","author":"H von Euler","year":"2011","unstructured":"von Euler H, Eriksson S. Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases. Vet Comp Oncol. 2011;9(1):1\u201315. https:\/\/doi.org\/10.1111\/j.1476-5829.2010.00238.x.","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"399_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/vco.12052","volume":"13","author":"K Selting","year":"2015","unstructured":"Selting K, Sharp C, Ringhold R, Knouse J. Serum thymidine kinase 1 and C-reactive protein as biomarkers for screening clinically healthy dogs for occult disease. Vet Comp Oncol. 2015;13(4):373\u201384. https:\/\/doi.org\/10.1111\/vco.12052.","journal-title":"Vet Comp Oncol"},{"issue":"2","key":"399_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.tvjl.2015.01.019","volume":"205","author":"S Larsdotter","year":"2015","unstructured":"Larsdotter S, Nostell K, von Euler H. Serum thymidine kinase activity in clinically healthy and diseased horses: a potential marker for lymphoma. Vet J. 2015;205(2):313\u20136. https:\/\/doi.org\/10.1016\/j.tvjl.2015.01.019.","journal-title":"Vet J"},{"issue":"3","key":"399_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0749-0739(17)30191-8","volume":"14","author":"A Th\u00e9on","year":"1998","unstructured":"Th\u00e9on A. Intralesional and topical chemotherapy and immunotherapy. Vet Clin North Am Equine Pract. 1998;14(3):659\u201371. https:\/\/doi.org\/10.1016\/S0749-0739(17)30191-8.","journal-title":"Vet Clin North Am Equine Pract"},{"issue":"2","key":"399_CR17","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/jvim.15411","volume":"33","author":"D Luethy","year":"2018","unstructured":"Luethy D, Frimberger A, Bedenice D, Byrne B, Groover E, Gardner R, et al. Retrospective evaluation of clinical outcome after chemotherapy for lymphoma in 15 equids (1991-2017). J Vet Intern Med. 2018;33(2):953\u201360. https:\/\/doi.org\/10.1111\/jvim.15411.","journal-title":"J Vet Intern Med"},{"key":"399_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.tvjl.2015.06.010","volume":"207","author":"M Vissani","year":"2016","unstructured":"Vissani M, Thiry E, Dal Pozzo F, Barrandeguy M. Antiviral agents against equid alphaherpesviruses: current status and perspectives. Vet J. 2016;207:38\u201344. https:\/\/doi.org\/10.1016\/j.tvjl.2015.06.010.","journal-title":"Vet J"},{"issue":"52","key":"399_CR19","doi-asserted-by":"publisher","first-page":"17970","DOI":"10.1073\/pnas.0406332102","volume":"101","author":"M Welin","year":"2004","unstructured":"Welin M, Kosinska U, Mikkelsen N, Carnrot C, Zhu C, Wang L, et al. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci U S A. 2004;101(52):17970\u20135. https:\/\/doi.org\/10.1073\/pnas.0406332102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"399_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2091-13-12","volume":"13","author":"H Sharif","year":"2012","unstructured":"Sharif H, Jagarlamudi K, Wang L, He E, Eriksson S. Quaternary structures of recombinant, cellular, and serum forms of thymidine kinase 1 from dogs and humans. BMC Biochem. 2012;13:12.","journal-title":"BMC Biochem"},{"issue":"14","key":"399_CR21","doi-asserted-by":"publisher","first-page":"9032","DOI":"10.1016\/S0021-9258(18)31547-3","volume":"266","author":"B Munch-Petersen","year":"1991","unstructured":"Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 1991;266(14):9032\u20138. https:\/\/doi.org\/10.1016\/S0021-9258(18)31547-3.","journal-title":"J Biol Chem"},{"issue":"21","key":"399_CR22","doi-asserted-by":"publisher","first-page":"15621","DOI":"10.1016\/S0021-9258(18)82301-8","volume":"268","author":"B Munch-Petersen","year":"1993","unstructured":"Munch-Petersen B, Tyrsted G, Cloos L. Reversible ATP-dependent transition between two forms of human cytosolic thymidine kinase with different enzymatic properties. J Biol Chem. 1993;268(21):15621\u20135. https:\/\/doi.org\/10.1016\/S0021-9258(18)82301-8.","journal-title":"J Biol Chem"},{"issue":"1","key":"399_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.tvjl.2012.03.006","volume":"194","author":"H Sharif","year":"2012","unstructured":"Sharif H, von Euler H, Westberg S, He E, Wang L, Eriksson S. A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma. Vet J. 2012;194(1):40\u20137. https:\/\/doi.org\/10.1016\/j.tvjl.2012.03.006.","journal-title":"Vet J"},{"issue":"51","key":"399_CR24","doi-asserted-by":"publisher","first-page":"16993","DOI":"10.1021\/bi9908843","volume":"38","author":"J Wang","year":"1999","unstructured":"Wang J, Choudhury D, Chattopadhyaya J, Eriksson S. Stereoisomeric selectivity of human deoxyribonucleoside kinases. Biochemistry. 1999;38(51):16993\u20139. https:\/\/doi.org\/10.1021\/bi9908843.","journal-title":"Biochemistry"},{"issue":"6","key":"399_CR25","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jevs.2013.12.017","volume":"34","author":"K Vander Werf","year":"2014","unstructured":"Vander Werf K, Davis E, Janardhan K, Bawa B, Bolin S, Almes K. Identification of equine herpesvirus 5 in horses with lymphoma. J Equine Vet Sci. 2014;34(6):738\u201342. https:\/\/doi.org\/10.1016\/j.jevs.2013.12.017.","journal-title":"J Equine Vet Sci"},{"issue":"5","key":"399_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2460\/javma.2004.224.733","volume":"224","author":"M Saulez","year":"2004","unstructured":"Saulez M, Schlipf J Jr, Cebra C, McDonough S, Bird K. Use of chemotherapy for treatment of a mixed-cell thoracic lymphoma in a horse. J Am Vet Med Assoc. 2004;224(5):733\u20138. https:\/\/doi.org\/10.2460\/javma.2004.224.733.","journal-title":"J Am Vet Med Assoc"},{"issue":"2","key":"399_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/jvim.12050","volume":"27","author":"K Vander Werf","year":"2013","unstructured":"Vander Werf K, Davis E. Disease remission in a horse with EHV-5-associated lymphoma. J Vet Intern Med. 2013;27(2):387\u20139. https:\/\/doi.org\/10.1111\/jvim.12050.","journal-title":"J Vet Intern Med"},{"key":"399_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mrfmmm.2005.06.019","volume":"592","author":"P Schulte","year":"2011","unstructured":"Schulte P. The use of biomarkers in surveillance, medical screening, and intervention. Mutat Res. 2011;592:155\u201363.","journal-title":"Mutat Res"},{"issue":"5","key":"399_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3892\/mco.2020.2002","volume":"12","author":"L Dang","year":"2020","unstructured":"Dang L, Ma H, Hei A, Xu S, Zhou J, He E, et al. A meta-analysis of serological thymidine kinase 1 as a marker for colorectal benign and malignant tumor risk assessment. Mol Clin Oncol. 2020;12(5):440\u201350. https:\/\/doi.org\/10.3892\/mco.2020.2002.","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"399_CR30","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.tvjl.2013.05.036","volume":"197","author":"J Kiran Kumar","year":"2013","unstructured":"Kiran Kumar J, Sharif H, Westberg S, von Euler H, Eriksson S. High levels of inactive thymidine kinase 1 polypeptide detected in sera from dogs with solid tumours by immunoaffinity method: implications for in vitro diagnostics. Vet J. 2013;197(3):854\u201360. https:\/\/doi.org\/10.1016\/j.tvjl.2013.05.036.","journal-title":"Vet J"},{"issue":"2","key":"399_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1042\/bj3510469","volume":"351","author":"L Wang","year":"2000","unstructured":"Wang L, Eriksson S. Cloning and characterization of full length mouse thymidine kinase 2: the N-terminal sequence directs import of the precursor protein into mitochondria. Biochem J. 2000;351(2):469\u201376. https:\/\/doi.org\/10.1042\/bj3510469.","journal-title":"Biochem J"},{"issue":"1","key":"399_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1006\/abio.2001.5191","volume":"295","author":"P Schelling","year":"2001","unstructured":"Schelling P, Folkers G, Scapozza L. A spectrophotometric assay for quantitative determination of Kcat of herpes simplex virus type 1 thymidine kinase substrates. Anal Biochem. 2001;295(1):82\u20137. https:\/\/doi.org\/10.1006\/abio.2001.5191.","journal-title":"Anal Biochem"},{"issue":"9","key":"399_CR33","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1110\/ps.034199.107","volume":"17","author":"C Carnrot","year":"2008","unstructured":"Carnrot C, Wang L, Topalis D, Eriksson S. Mechanisms of substrate selectivity for bacillus anthracis thymidylate kinase. Protein Sci. 2008;17(9):1486\u201393. https:\/\/doi.org\/10.1110\/ps.034199.107.","journal-title":"Protein Sci"},{"issue":"12","key":"399_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.17236\/sat00283","volume":"162","author":"G Christen","year":"2020","unstructured":"Christen G, Precht C, van der Kolk J, Fouch\u00e9 N, Gerber V. Age over 25 years, but not plasma adrenocorticotropic hormone concentration above the seasonally adjusted reference range is predictive for eadiographically assessed changes of chronic laminitis in elderly horses. Schweiz Arch Tierheilkd. 2020;162(12):781\u2013685. https:\/\/doi.org\/10.17236\/sat00283.","journal-title":"Schweiz Arch Tierheilkd"}],"container-title":["BMC Molecular and Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12860-021-00399-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12860-021-00399-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12860-021-00399-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T09:06:51Z","timestamp":1639472811000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmolcellbiol.biomedcentral.com\/articles\/10.1186\/s12860-021-00399-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1186\/s12860-021-00399-x","relation":{},"ISSN":["2661-8850"],"issn-type":[{"value":"2661-8850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"27 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent to participation from the horse owners was obtained prior to the experiment. The project was submitted for and approved by the Animal Experimentation Committees of the Cantons of Bern (BE110\/15, BE41\/19+) and Jura (JU EXPE01\/14+), Switzerland. Serum samples were collected from patients with informed consent forms from their owners. All experiments were carried out in accordance with the ARRIVE guidelines () and regulations presented by the Swedish Ethical Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HS is employed by Alertix Veterinary Diagnostic AB; SE is a consultant and cofounder, and HR is member of the scientific advisory board. SE, HR, HS, and LW own shares of the same company. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}